RDF/XMLNTriplesTurtleShow queryShare
SubjectPredicateObject
http://purl.uniprot.org/citations/24485087http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/24485087http://www.w3.org/2000/01/rdf-schema#comment"

Background

The HECT family ubiquitin ligase Smurf2 regulates cell polarity, migration, division, differentiation and death, by targeting diverse substrates that are critical for receptor signaling, cytoskeleton, chromatin remodeling and transcription. Recent studies suggest that Smurf2 functions as a tumor suppressor in mice. However, no inactivating mutation of SMURF2 has been reported in human, and information about Smurf2 expression in human cancer remains limited or complicated. Here we demonstrate that Smurf2 expression is downregulated in human breast cancer tissues, especially of the triple-negative subtype, and address the mechanism of Smurf2 downregulation in triple-negative breast cancer cells.

Methods

Human breast cancer tissues (47 samples expressing estrogen receptor (ER) and 43 samples with triple-negative status) were examined by immunohistochemistry for the expression of Smurf2. Ten widely-studied human breast cancer cell lines were examined for the expression of Smurf2. Furthermore, microRNA-mediated regulation of Smurf2 was investigated in triple-negative cancer cell lines.

Results

Immunohistochemical analysis showed that benign mammary epithelial cells expressed high levels of Smurf2, so did cells in ductal carcinomas in situ. In contrast, invasive ductal carcinomas showed focal or diffuse decrease in Smurf2 expression, which was observed more frequently in triple-negative tumors than in ER-positive tumors. Consistently, human triple-negative breast cancer cell lines such as BT549, MDA-MB-436, DU-4475 and MDA-MB-468 cells showed significantly lower expression of Smurf2 protein, compared to ER + or HER2+ cell lines. Studies using quantitative PCR and specific microRNA inhibitors indicated that increased expression of miR-15a, miR-15b, miR-16 and miR-128 was involved in Smurf2 downregulation in those triple-negative cancer cell lines, which have mutations in the retinoblastoma (RB) gene. Forced expression of RB increased levels of Smurf2 protein with concomitant decreases in the expression of the microRNAs.

Conclusions

This study provides evidence of posttranscriptional downregulation of Smurf2 in triple-negative breast cancers, and demonstrates that the loss of RB function is involved in microRNA-mediated interference with Smurf2 translation. The new link from RB inactivation to Smurf2 downregulation is likely to play a role in malignant phenotypes of triple-negative breast cancer cells."xsd:string
http://purl.uniprot.org/citations/24485087http://purl.org/dc/terms/identifier"doi:10.1186/1471-2407-14-57"xsd:string
http://purl.uniprot.org/citations/24485087http://purl.uniprot.org/core/author"Liu X."xsd:string
http://purl.uniprot.org/citations/24485087http://purl.uniprot.org/core/author"Sun L."xsd:string
http://purl.uniprot.org/citations/24485087http://purl.uniprot.org/core/author"Zhou Y."xsd:string
http://purl.uniprot.org/citations/24485087http://purl.uniprot.org/core/author"Gu X."xsd:string
http://purl.uniprot.org/citations/24485087http://purl.uniprot.org/core/author"Kiyokawa H."xsd:string
http://purl.uniprot.org/citations/24485087http://purl.uniprot.org/core/author"Rademaker A.W."xsd:string
http://purl.uniprot.org/citations/24485087http://purl.uniprot.org/core/author"Flowers A.B."xsd:string
http://purl.uniprot.org/citations/24485087http://purl.uniprot.org/core/date"2014"xsd:gYear
http://purl.uniprot.org/citations/24485087http://purl.uniprot.org/core/name"BMC Cancer"xsd:string
http://purl.uniprot.org/citations/24485087http://purl.uniprot.org/core/pages"57"xsd:string
http://purl.uniprot.org/citations/24485087http://purl.uniprot.org/core/title"Downregulation of Smurf2, a tumor-suppressive ubiquitin ligase, in triple-negative breast cancers: involvement of the RB-microRNA axis."xsd:string
http://purl.uniprot.org/citations/24485087http://purl.uniprot.org/core/volume"14"xsd:string
http://purl.uniprot.org/citations/24485087http://www.w3.org/2004/02/skos/core#exactMatchhttp://purl.uniprot.org/pubmed/24485087
http://purl.uniprot.org/citations/24485087http://xmlns.com/foaf/0.1/primaryTopicOfhttps://pubmed.ncbi.nlm.nih.gov/24485087
http://purl.uniprot.org/uniprot/#_A0A385FS38-mappedCitation-24485087http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/24485087
http://purl.uniprot.org/uniprot/#_A0A385FS40-mappedCitation-24485087http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/24485087
http://purl.uniprot.org/uniprot/#_A0A385FS41-mappedCitation-24485087http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/24485087
http://purl.uniprot.org/uniprot/#_A0A385FS44-mappedCitation-24485087http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/24485087
http://purl.uniprot.org/uniprot/#_A0A385FS48-mappedCitation-24485087http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/24485087
http://purl.uniprot.org/uniprot/#_A0A385FS65-mappedCitation-24485087http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/24485087
http://purl.uniprot.org/uniprot/#_A0A385FS12-mappedCitation-24485087http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/24485087
http://purl.uniprot.org/uniprot/#_A0A385FS25-mappedCitation-24485087http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/24485087